Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice

Daniele Raggi; Robert A Huddart

doi:10.1016/j.medj.2024.11.004

Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice

Med. 2024 Dec 13;5(12):1456-1458. doi: 10.1016/j.medj.2024.11.004.

Authors

Daniele Raggi¹, Robert A Huddart²

Affiliations

¹ Genitourinary Oncology, The Royal Marsden Hospital NHS Foundation Trust, Sutton, London, UK. Electronic address: [email protected].
² Genitourinary Oncology, The Royal Marsden Hospital NHS Foundation Trust, Sutton, London, UK; The Institute of Cancer Research, London, UK.

PMID: 39674170
DOI: 10.1016/j.medj.2024.11.004

Abstract

The phase 3 NIAGARA trial¹ demonstrated a statistically significant improvement in event-free and overall survival in cisplatin-eligible patients with muscle-invasive bladder cancer treated with perioperative durvalumab in combination with neoadjuvant chemotherapy, compared to neoadjuvant chemotherapy alone. The combination was manageable and did not adversely impact surgery. NIAGARA positions perioperative durvalumab with chemotherapy as a potential new standard of care.

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / administration & dosage
Cisplatin / therapeutic use
Clinical Trials, Phase III as Topic
Humans
Neoadjuvant Therapy* / methods
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / therapy

Substances

Antibodies, Monoclonal
durvalumab
Cisplatin